<DOC>
	<DOC>NCT00515463</DOC>
	<brief_summary>The purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled syringe (PFS) and vial at 6 months in postmenopausal women with low bone mineral density (BMD).</brief_summary>
	<brief_title>A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Patients who have successfully completed the 20050141 study (NCT00330460): Must have received all SC investigational product administrations in 20050141 Must not have taken any proscribed therapies in 20050141 Subjects who were in the alendronate or denosumab treatment group are allowed Provide signed informed consent before any studyspecific procedures are conducted Any disorder that, in the opinion of the investigator, may compromise the ability of the patient to give written informed consent and/or comply with study procedures including: Any physical or psychiatric disorder Or evidence of alcohol or substance abuse in the last 12 months Any clinical evidence, in the medical judgement of the investigator, of the following medical conditions: Impaired thyroid function (subsequent to treatment) Impaired hepatic function Impaired renal function Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigen Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>AMG 162</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Pre-filled syringe</keyword>
</DOC>